MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year

MaaT Pharma is racing its microbiome therapy into a late-phase cancer clinical trial. Rather than take the current phase 1b to its planned conclusion, MaaT is wrapping the trial up early to accelerate its push into a larger study of acute myeloid leukemia (AML) patients.